Enhanced inhibition of murine tumor and human breast tumor xenografts using targeted delivery of an antibody-endostatin fusion protein

Hyun Mi Cho, Joseph D Rosenblatt, Young Sook Kang, M. Luisa Iruela-Arispe, Sherie L. Morrison, Manuel L. Penichet, Young Guen Kwon, Tae Woong Kim, Keith A Webster, Hovav Nechustan, Seung-Uon Shin

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Endostatin can inhibit angiogenesis and tumor growth in mice. A potential limitation of endostatin as an antitumor agent in humans is the short serum half-life of the protein that may decrease effective concentration at the site of tumor and necessitate frequent dosing. In an effort to improve antitumor activity, endostatin was fused to an antibody specific for the tumor-selective HER2 antigen to create an antibody-endostatin fusion protein (anti-HER2 IgG3-endostatin). Normal endostatin rapidly cleared from serum in mice (T1/2 2, = 0.6 - 3.8 hours), whereas anti-HER2 IgG3-endostatin had a prolonged half-life (90% intact; T1/2 2, 40.2-44.0 hours). Antigen-specific targeting of anti-HER2 IgG3-endostatin was evaluated in BALB/c mice implanted with CT26 tumors or CT26 tumors engineered to express the HER2 antigen (CT26-HER2). Radio-iodinated anti-HER2 IgG3-endostatin preferentially localized to CT26-HER2 tumors relative to CT26 tumors. Administration of anti-HER2 IgG3-endostatin to mice showed preferential inhibition of CT26-HER2 tumor growth compared with CT26. Anti-HER2 IgG3-endostatin also markedly inhibited the growth of human breast cancer SK-BR-3 xenografts in severe combined immunodeficient mice. Anti-HER2 IgG3-endostatin inhibited tumor growth significantly more effectively than endostatin, anti-HER2 IgG3 antibody, or the combination of antibody and endostatin. CT26-HER2 tumors treated with the endostatin fusion protein had decreased blood vessel density and branching compared with untreated CT26-HER2 or CT26 treated with the fusion protein. The enhanced effectiveness of anti-HER2 IgG3-endostatin may be due to a longer half-life, improved serum stability, and selective targeting of endostatin to tumors, resulting in decreased angiogenesis. Linking of an antiangiogenic protein, such as endostatin, to a targeting antibody represents a promising and versatile approach to antitumor therapy.

Original languageEnglish
Pages (from-to)956-967
Number of pages12
JournalMolecular Cancer Therapeutics
Volume4
Issue number6
DOIs
StatePublished - Jun 1 2005

Fingerprint

Endostatins
Heterografts
Breast Neoplasms
Antibodies
Neoplasms
Proteins
Immunoglobulin G
Half-Life
Growth
Antigens
Serum
Neoplasm Antibodies

ASJC Scopus subject areas

  • Oncology
  • Drug Discovery
  • Pharmacology

Cite this

Enhanced inhibition of murine tumor and human breast tumor xenografts using targeted delivery of an antibody-endostatin fusion protein. / Cho, Hyun Mi; Rosenblatt, Joseph D; Kang, Young Sook; Iruela-Arispe, M. Luisa; Morrison, Sherie L.; Penichet, Manuel L.; Kwon, Young Guen; Kim, Tae Woong; Webster, Keith A; Nechustan, Hovav; Shin, Seung-Uon.

In: Molecular Cancer Therapeutics, Vol. 4, No. 6, 01.06.2005, p. 956-967.

Research output: Contribution to journalArticle

Cho, Hyun Mi ; Rosenblatt, Joseph D ; Kang, Young Sook ; Iruela-Arispe, M. Luisa ; Morrison, Sherie L. ; Penichet, Manuel L. ; Kwon, Young Guen ; Kim, Tae Woong ; Webster, Keith A ; Nechustan, Hovav ; Shin, Seung-Uon. / Enhanced inhibition of murine tumor and human breast tumor xenografts using targeted delivery of an antibody-endostatin fusion protein. In: Molecular Cancer Therapeutics. 2005 ; Vol. 4, No. 6. pp. 956-967.
@article{7160c835464144be92bb1a96f3b6dc8b,
title = "Enhanced inhibition of murine tumor and human breast tumor xenografts using targeted delivery of an antibody-endostatin fusion protein",
abstract = "Endostatin can inhibit angiogenesis and tumor growth in mice. A potential limitation of endostatin as an antitumor agent in humans is the short serum half-life of the protein that may decrease effective concentration at the site of tumor and necessitate frequent dosing. In an effort to improve antitumor activity, endostatin was fused to an antibody specific for the tumor-selective HER2 antigen to create an antibody-endostatin fusion protein (anti-HER2 IgG3-endostatin). Normal endostatin rapidly cleared from serum in mice (T1/2 2, = 0.6 - 3.8 hours), whereas anti-HER2 IgG3-endostatin had a prolonged half-life (90{\%} intact; T1/2 2, 40.2-44.0 hours). Antigen-specific targeting of anti-HER2 IgG3-endostatin was evaluated in BALB/c mice implanted with CT26 tumors or CT26 tumors engineered to express the HER2 antigen (CT26-HER2). Radio-iodinated anti-HER2 IgG3-endostatin preferentially localized to CT26-HER2 tumors relative to CT26 tumors. Administration of anti-HER2 IgG3-endostatin to mice showed preferential inhibition of CT26-HER2 tumor growth compared with CT26. Anti-HER2 IgG3-endostatin also markedly inhibited the growth of human breast cancer SK-BR-3 xenografts in severe combined immunodeficient mice. Anti-HER2 IgG3-endostatin inhibited tumor growth significantly more effectively than endostatin, anti-HER2 IgG3 antibody, or the combination of antibody and endostatin. CT26-HER2 tumors treated with the endostatin fusion protein had decreased blood vessel density and branching compared with untreated CT26-HER2 or CT26 treated with the fusion protein. The enhanced effectiveness of anti-HER2 IgG3-endostatin may be due to a longer half-life, improved serum stability, and selective targeting of endostatin to tumors, resulting in decreased angiogenesis. Linking of an antiangiogenic protein, such as endostatin, to a targeting antibody represents a promising and versatile approach to antitumor therapy.",
author = "Cho, {Hyun Mi} and Rosenblatt, {Joseph D} and Kang, {Young Sook} and Iruela-Arispe, {M. Luisa} and Morrison, {Sherie L.} and Penichet, {Manuel L.} and Kwon, {Young Guen} and Kim, {Tae Woong} and Webster, {Keith A} and Hovav Nechustan and Seung-Uon Shin",
year = "2005",
month = "6",
day = "1",
doi = "10.1158/1535-7163.MCT-04-0321",
language = "English",
volume = "4",
pages = "956--967",
journal = "Molecular Cancer Therapeutics",
issn = "1535-7163",
publisher = "American Association for Cancer Research Inc.",
number = "6",

}

TY - JOUR

T1 - Enhanced inhibition of murine tumor and human breast tumor xenografts using targeted delivery of an antibody-endostatin fusion protein

AU - Cho, Hyun Mi

AU - Rosenblatt, Joseph D

AU - Kang, Young Sook

AU - Iruela-Arispe, M. Luisa

AU - Morrison, Sherie L.

AU - Penichet, Manuel L.

AU - Kwon, Young Guen

AU - Kim, Tae Woong

AU - Webster, Keith A

AU - Nechustan, Hovav

AU - Shin, Seung-Uon

PY - 2005/6/1

Y1 - 2005/6/1

N2 - Endostatin can inhibit angiogenesis and tumor growth in mice. A potential limitation of endostatin as an antitumor agent in humans is the short serum half-life of the protein that may decrease effective concentration at the site of tumor and necessitate frequent dosing. In an effort to improve antitumor activity, endostatin was fused to an antibody specific for the tumor-selective HER2 antigen to create an antibody-endostatin fusion protein (anti-HER2 IgG3-endostatin). Normal endostatin rapidly cleared from serum in mice (T1/2 2, = 0.6 - 3.8 hours), whereas anti-HER2 IgG3-endostatin had a prolonged half-life (90% intact; T1/2 2, 40.2-44.0 hours). Antigen-specific targeting of anti-HER2 IgG3-endostatin was evaluated in BALB/c mice implanted with CT26 tumors or CT26 tumors engineered to express the HER2 antigen (CT26-HER2). Radio-iodinated anti-HER2 IgG3-endostatin preferentially localized to CT26-HER2 tumors relative to CT26 tumors. Administration of anti-HER2 IgG3-endostatin to mice showed preferential inhibition of CT26-HER2 tumor growth compared with CT26. Anti-HER2 IgG3-endostatin also markedly inhibited the growth of human breast cancer SK-BR-3 xenografts in severe combined immunodeficient mice. Anti-HER2 IgG3-endostatin inhibited tumor growth significantly more effectively than endostatin, anti-HER2 IgG3 antibody, or the combination of antibody and endostatin. CT26-HER2 tumors treated with the endostatin fusion protein had decreased blood vessel density and branching compared with untreated CT26-HER2 or CT26 treated with the fusion protein. The enhanced effectiveness of anti-HER2 IgG3-endostatin may be due to a longer half-life, improved serum stability, and selective targeting of endostatin to tumors, resulting in decreased angiogenesis. Linking of an antiangiogenic protein, such as endostatin, to a targeting antibody represents a promising and versatile approach to antitumor therapy.

AB - Endostatin can inhibit angiogenesis and tumor growth in mice. A potential limitation of endostatin as an antitumor agent in humans is the short serum half-life of the protein that may decrease effective concentration at the site of tumor and necessitate frequent dosing. In an effort to improve antitumor activity, endostatin was fused to an antibody specific for the tumor-selective HER2 antigen to create an antibody-endostatin fusion protein (anti-HER2 IgG3-endostatin). Normal endostatin rapidly cleared from serum in mice (T1/2 2, = 0.6 - 3.8 hours), whereas anti-HER2 IgG3-endostatin had a prolonged half-life (90% intact; T1/2 2, 40.2-44.0 hours). Antigen-specific targeting of anti-HER2 IgG3-endostatin was evaluated in BALB/c mice implanted with CT26 tumors or CT26 tumors engineered to express the HER2 antigen (CT26-HER2). Radio-iodinated anti-HER2 IgG3-endostatin preferentially localized to CT26-HER2 tumors relative to CT26 tumors. Administration of anti-HER2 IgG3-endostatin to mice showed preferential inhibition of CT26-HER2 tumor growth compared with CT26. Anti-HER2 IgG3-endostatin also markedly inhibited the growth of human breast cancer SK-BR-3 xenografts in severe combined immunodeficient mice. Anti-HER2 IgG3-endostatin inhibited tumor growth significantly more effectively than endostatin, anti-HER2 IgG3 antibody, or the combination of antibody and endostatin. CT26-HER2 tumors treated with the endostatin fusion protein had decreased blood vessel density and branching compared with untreated CT26-HER2 or CT26 treated with the fusion protein. The enhanced effectiveness of anti-HER2 IgG3-endostatin may be due to a longer half-life, improved serum stability, and selective targeting of endostatin to tumors, resulting in decreased angiogenesis. Linking of an antiangiogenic protein, such as endostatin, to a targeting antibody represents a promising and versatile approach to antitumor therapy.

UR - http://www.scopus.com/inward/record.url?scp=21344466557&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=21344466557&partnerID=8YFLogxK

U2 - 10.1158/1535-7163.MCT-04-0321

DO - 10.1158/1535-7163.MCT-04-0321

M3 - Article

VL - 4

SP - 956

EP - 967

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

SN - 1535-7163

IS - 6

ER -